Bellicum Pharmaceuticals (BLCM) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Bellicum Pharmaceuticals, Inc. has finalized the sale of its research and development programs, including the CaspaCIDe safety switch and the dual-switch GoCAR-T technology, to The University of Texas M. D. Anderson Cancer Center for $8.1 million. Following a lack of quorum at the initial special meeting, a reconvened meeting saw stockholders approve both the asset sale and the company’s dissolution. The successful vote paves the way for the company to liquidate and dissolve, as outlined in the approved Plan of Dissolution, subject to legal and regulatory obligations.
For further insights into BLCM stock, check out TipRanks’ Stock Analysis page.
